Italian-based international pharmaceutical group Recordati is one of the world's most active companies in the field of research, development and marketing of treatments for rare diseases. Since the coronavirus pandemic started, Recordati has diverted medicines and funds with a cumulative value of €2 million to hospitals across Italy, Spain and Turkey, and is planning further donations of €3 million over time.

Recordati is also planning to supply those medicines in its portfolio that are particularly useful for patients affected by COVID-19 free of charge.